Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Drugs Ltd held an Extra-Ordinary General Meeting on 31 July 2025 via video conferencing. Three resolutions were passed: (1) an ordinary resolution to increase the authorised share capital and amend the Memorandum of Association, approved with 99.9999% votes in favour; (2) a special resolution for issuance of equity shares on a preferential basis to promoter and non-promoter persons, approved with 99.9991% in favour; and (3) a special resolution to issue warrants convertible into equity shares to promoters and identified non-promoters on a preferential basis, also approved with 99.9991% in favour. Promoters holding 54,39,204 shares voted unanimously in favour of all three resolutions. Public participation was very low, with only about 0.17% of public shares being voted. No invalid votes were reported. The scrutinizer, PSK & Associates, confirmed all resolutions were passed with the requisite majority.
The resolutions collectively enable Concord Drugs to raise capital through a preferential share and warrant issue, which may lead to dilution for existing public shareholders. The near-unanimous approval was largely driven by promoter support (100% in favour), while public participation was minimal.